MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, WGS made $116,743,000 in revenue. -$7,445,000 in net income. Net profit margin of -6.38%.

Income Overview

Revenue
$116,743,000
Net Income
-$7,445,000
Net Profit Margin
-6.38%
Unit: Dollar
Revenue Breakdown
    • Gene Dx
    • Legacy Sema4
    • Gene Dx
    • Legacy Sema4
Revenue Breakdown
    • Gene Dx
    • Legacy Sema4

Unit: Dollar
Income Statement
2025-09-30
2025-06-30
2025-03-31
2024-12-31
Total revenue
116,743,000 102,692,000 87,115,000 75,094,333.333
Cost of services
32,216,000 31,790,000 28,639,000 27,336,000
Gross profit
84,527,000 70,902,000 58,476,000 48,856,000
Other operating expenses, net
----877,666.667
Research and development
19,829,000 15,079,000 12,577,000 11,352,333.333
Selling and marketing
23,510,000 19,448,000 18,316,000 16,782,000
General and administrative
44,439,000 27,415,000 32,134,000 24,988,333.333
Loss (income) from operations
-3,251,000 8,960,000 -4,551,000 -5,144,333.333
Change in fair value of financial liabilities
-3,401,000 2,181,000 -1,100,000 -
Change in fair value of warrants and contingent liabilities
----3,342,500
Interest expense, net
-562,000 -817,000 -640,000 -729,666.667
Other (expense) income, net
-174,000 239,000 209,000 -4,719,333.333
Total non-operating expense, net
-4,137,000 1,603,000 -1,531,000 -9,612,333.333
Loss before income taxes
-7,388,000 10,563,000 -6,082,000 -14,756,666.667
Income tax (expense) benefit
247,000 -246,000 447,000 -98,666.667
Net loss
-7,635,000 10,809,000 -6,529,000 -14,658,000
Unrealized gain related to available for sale securities, net
190,000 -93,000 75,000 -18,000
Comprehensive loss
-7,445,000 10,716,000 -6,454,000 -14,676,000
Earnings (loss) per share, class a common stock- basic (in dollars per share)
-0.38 -0.23 -0.543
Earnings (loss) per share, class a common stock- diluted (in dollars per share)
-0.36 -0.23 -0.543
Weighted average shares outstanding of class a common stock - basic (in shares)
-28,579,704 28,147,948 -68,257.667
Weighted average shares outstanding of class a common stock - diluted (in shares)
-29,753,933 28,147,948 -68,257.667
Basic loss per share, class a common stock (in dollars per share)
-0.27 ---
Diluted loss per share, class a common stock (in dollars per share)
-0.27 ---
Weighted-average shares outstanding of class a common stock - basic (in shares)
28,797,730 ---
Weighted-average shares outstanding of class a common stock - diluted (in shares)
28,797,730 ---
Unit: Dollar

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Comprehensive loss-$7,445,000 Unrealized gain related toavailable for sale...$190,000 Legacy Sema4$1,717,000 Gene Dx$1,503,000 Legacy Sema4$329,000 Gene Dx$113,194,000 Net loss-$7,635,000 Product And ServiceOther$3,220,000 Diagnostic Test$113,523,000 Income tax (expense)benefit$247,000 Loss before incometaxes-$7,388,000 Total revenue$116,743,000 Total non-operatingexpense, net-$4,137,000 Loss (income) fromoperations-$3,251,000 Gross profit$84,527,000 Cost of services$32,216,000 Other (expense)income, net-$174,000 Interest expense, net-$562,000 Change in fair value offinancial liabilities-$3,401,000 General andadministrative$44,439,000 Selling and marketing$23,510,000 Research and development$19,829,000

GeneDx Holdings Corp. (WGS)

GeneDx Holdings Corp. (WGS)